Company’s 36-month beta value is 2.09.
The public float for CDT is 39.09M, and currently, short sellers hold a 2.74% ratio of that floaft. The average trading volume of CDT on September 30, 2024 was 12.99M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CDT) stock’s latest price update
The stock price of Conduit Pharmaceuticals Inc (NASDAQ: CDT) has dropped by -4.23 compared to previous close of 0.13. Despite this, the company has seen a fall of -4.91% in its stock price over the last five trading days. investorplace.com reported 2024-08-14 that Conduit Pharmaceuticals (NASDAQ: CDT ) stock is up on Wednesday following a shareholder update concerning a major investor in the company. New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited holds a 14.8% stake in CDT stock.
CDT’s Market Performance
Conduit Pharmaceuticals Inc (CDT) has experienced a -4.91% fall in stock performance for the past week, with a -7.69% drop in the past month, and a -87.93% drop in the past quarter. The volatility ratio for the week is 5.65%, and the volatility levels for the past 30 days are at 8.68% for CDT. The simple moving average for the past 20 days is -7.76% for CDT’s stock, with a -94.76% simple moving average for the past 200 days.
CDT Trading at -27.02% from the 50-Day Moving Average
After a stumble in the market that brought CDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.63% of loss for the given period.
Volatility was left at 8.68%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares sank -2.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.60% lower at present.
During the last 5 trading sessions, CDT fell by -4.99%, which changed the moving average for the period of 200-days by -98.02% in comparison to the 20-day moving average, which settled at $0.1301. In addition, Conduit Pharmaceuticals Inc saw -97.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDT starting from Regan Andrew, who sale 10,244,392 shares at the price of $0.32 back on Jul 16 ’24. After this action, Regan Andrew now owns 1,691,727 shares of Conduit Pharmaceuticals Inc, valued at $3,246,448 using the latest closing price.
Regan Andrew, the Director of Conduit Pharmaceuticals Inc, sale 1,514,100 shares at $0.26 during a trade that took place back on Jul 17 ’24, which means that Regan Andrew is holding 177,627 shares at $391,092 based on the most recent closing price.
Stock Fundamentals for CDT
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.38 for the gross margin
The net margin for Conduit Pharmaceuticals Inc stands at -0.0. The total capital return value is set at -17.95. Equity return is now at value -89.65, with -38.44 for asset returns.
Based on Conduit Pharmaceuticals Inc (CDT), the company’s capital structure generated -0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -8.25. The debt to equity ratio resting at -0.23. The interest coverage ratio of the stock is -13.1.
Currently, EBITDA for the company is -5.56 million with net debt to EBITDA at -0.54. When we switch over and look at the enterprise to sales, we see a ratio of 0.01. The receivables turnover for the company is 6063.89for trailing twelve months and the total asset turnover is 344.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.56.
Conclusion
In a nutshell, Conduit Pharmaceuticals Inc (CDT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
